Correlation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke Patients

References

• MONICA Project Principal Invest W. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol. 1988;41(2):105–114. doi:10.1016/0895-4356(88)90084-4
   PubMed Web of Science ®Google Scholar
• Hasan MS, Basri HB, Hin LP, Stanslas J. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Int J Neurosci. 2013;123(3):143–154. doi:10.3109/00207454.2012.744308
   PubMed Web of Science ®Google Scholar
• Uchiyama S, Goto S, Matsumoto M, et al. Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: results from 1-year outcomes in the Japanese REACH Registry. J Neurol Sci. 2009;287(1–2):45–51.
   PubMed Web of Science ®Google Scholar
• Pennlert J, Eriksson M, Carlberg B, Wiklund PG. Long-term risk and predictors of recurrent stroke beyond the acute phase. Stroke. 2014;45(6):1839–1841.
   PubMed Web of Science ®Google Scholar
• Sandercock P, Gubitz G, Foley P, Counsell C. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;2003(2):CD000029.
   Google Scholar
• Pepine CJ. Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient. J Am Coll Cardiol. 1998;32(4):1126–1128.
   PubMed Web of Science ®Google Scholar
• Collyer TC, Gray DJ, Sandhu R, Berridge J, Lyons G. Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by Thrombelastography® platelet mappingTM. BJA Br J Anaesth. 2009;102(4):492–498.
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee. Lancet Lond Eng. 1996;348(9038):1329–1339.
   PubMed Web of Science ®Google Scholar
• Murugappa S, Kunapuli SP. The role of ADP receptors in platelet function. Front Biosci J Virtual Libr. 2006;11:1977–1986.
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919–933. doi:10.1016/j.jacc.2010.04.047
   PubMed Web of Science ®Google Scholar
• Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag. 2015;11:133–148. doi:10.2147/VHRM.S44469
   PubMed Web of Science ®Google Scholar
• Amin AM, Sheau Chin L, Azri Mohamed Noor D, Abdul Kader MA, Kah Hay Y, Ibrahim B. The personalization of clopidogrel antiplatelet therapy: the role of integrative pharmacogenetics and pharmacometabolomics. Cardiol Res Pract. 2017;2017:1. doi:10.1155/2017/8062796
   Web of Science ®Google Scholar
• Gaglia MA, Torguson R, Pakala R, et al. Correlation between light transmission aggregometry, verifynow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Intervent Cardiol. 2011;24(6):529–534. doi:10.1111/j.1540-8183.2011.00670.x
   PubMed Web of Science ®Google Scholar
• Gachet C, Aleil B. Testing antiplatelet therapy. Eur Heart J Suppl. 2008;10(suppl_A):A28–34. doi:10.1093/eurheartj/sum081
   Web of Science ®Google Scholar
• Jakubowski J, Li Y, Small D, et al. A comparison of the verifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. J Cardiovasc Pharmacol. 2010;56(1):29–37. doi:10.1097/FJC.0b013e3181dd0ec2
   PubMed Web of Science ®Google Scholar
• Berg H. Restriction fragment length polymorphism analysis of PCR-Amplified Fragments (PCR-RFLP) and Gel electrophoresis - valuable tool for genotyping and genetic fingerprinting. gel electrophoresis - principles and basics. InTech; 2012. Available from: http://www.intechopen.com/books/gel-electrophoresis-principles-and-basics/restriction-fragment-length-polymorphism-analysis-of-pcr-amplified-fragments-pcr-rflp-and-related-te. Accessed December 19, 2022.
   Google Scholar
• Kristensen VN, Kelefiotis D, Kristensen T, Børresen-Dale AL. High-throughput methods for detection of genetic variation. BioTechniques. 2001;30(2):318–332. doi:10.2144/01302tt01
   PubMed Web of Science ®Google Scholar
• Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–743. doi:10.1161/CIR.0000000000000950
   PubMed Web of Science ®Google Scholar
• Appelros P, Stegmayr B, Terént A. Sex differences in stroke epidemiology: a systematic review. Stroke. 2009;40(4):1082–1090. doi:10.1161/STROKEAHA.108.540781
   PubMed Web of Science ®Google Scholar
• Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(2):517–584. doi:10.1161/STR.0b013e3181fcb238
   PubMed Web of Science ®Google Scholar
• Lau LH, Lew J, Borschmann K, Thijs V, Ekinci EI. Prevalence of diabetes and its effects on stroke outcomes: a meta-analysis and literature review. J Diabetes Investig. 2019;10(3):780–792. doi:10.1111/jdi.12932
   PubMed Web of Science ®Google Scholar
• Fukuoka T, Furuya D, Takeda H, et al. Evaluation of clopidogrel resistance in ischemic stroke patients. Intern Med Tokyo Jpn. 2011;50(1):31–35. doi:10.2169/internalmedicine.50.3713
   Google Scholar
• Hidayat R, Nabilah RA, Rasyid A, et al. Clopidogrel resistance among ischemic stroke patients and its risk factors in Indonesia. Acta Medica Acad. 2022;51(1):29–34. doi:10.5644/ama2006-124.367
   PubMedGoogle Scholar
• Kunapuli SP, Dorsam RT, Kim S, Quinton TM. Platelet purinergic receptors. Curr Opin Pharmacol. 2003;3(2):175–180. doi:10.1016/S1471-4892(03)00007-9
   PubMed Web of Science ®Google Scholar
• Conley PB, Delaney SM. Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. Curr Opin Hematol. 2003;10(5):333–338. doi:10.1097/00062752-200309000-00002
   PubMed Web of Science ®Google Scholar
• Pierre F, Annabelle D, Sophie G, et al. Adenosine diphosphate–induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation. 2003;108(8):989–995.
   PubMed Web of Science ®Google Scholar
• Staritz P, Kurz K, Stoll M, Giannitsis E, Katus HA, Ivandic BT. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol. 2009;133(3):341–345.
   PubMed Web of Science ®Google Scholar
• Cui G, Zhang S, Zou J, Chen Y, Chen H. P2Y12 receptor gene polymorphism and the risk of resistance to clopidogrel: a meta-analysis and review of the literature. Adv Clin Exp Med off Organ Wroclaw Med Univ. 2017;26(2):343–349.
   PubMed Web of Science ®Google Scholar
• Nie XY, Li JL, Zhang Y, et al. Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity. J Zhejiang Univ Sci B. 2017;18(1):37–47.
   PubMed Web of Science ®Google Scholar
• Danielak D, Pawlak K, Główka F, Karaźniewicz-łada M. Influence of genetic and epigenetic factors of P2Y12 receptor on the safety and efficacy of antiplatelet drugs. Cardiovasc Drugs Ther. 2022;2022:1. doi:10.1007/s10557-022-07370-8
   Google Scholar
• Legrand D, Barbato E, Chenu P, et al. The STIB score: a simple clinical test to predict clopidogrel resistance. Acta Cardiol. 2015;70(5):516–521.
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097–1105.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li M, Tang J and Chen X. 2017. Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives. Int. J. Environ. Res. Public Health. 14(3): 301.10.3390/ijerph14030301
   PubMed Web of Science ®Google Scholar
• Yin T, Miyata T. Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res. 2011;128:307–316.
   PubMed Web of Science ®Google Scholar